Register | Login
Intellectual Property Today
RFC Express - Document Management System
2013 Top Patent Firms
2013 Top Trademark Firms
Current Issue

Advertising Opportunities

Click Here

Email A Friend Back to Archived News

Provectus Pharmaceuticals Receives Patent in India for Lead Oncology Product

Wednesday, December 12, 2007

Patent Protects PV-10 and Additional Pipeline Products

Knoxville, TN -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) ( has received a patent in India protecting its lead oncology agent, PV-10, along with a number of related agents. The patent covers injectable and other forms of the drugs, including capsules, tablets, and oral suspensions and solutions. A range of active compounds are protected, each related to the active ingredient in PV-10.

"Obtaining patent protection in India for PV-10 and our additional pipeline products is a major milestone, assuring a viable route to access a market representing roughly one-fifth of the world’s population," noted Craig Dees, Ph.D., CEO of Provectus. "Additionally, as the Indian pharmaceutical industry becomes a larger player in the worldwide market, this protection establishes an important right of ownership for products sold or made in India."

Dees Continued: "The Company is seeking protection of its assets in key markets worldwide, and this patent further validates the value of our science and our global intellectual property strategy to build value for our shareholders. As we focus on clinical development of our lead therapeutic products, PV-10 for cancer and PH-10 for dermatology, we believe that aggressively protecting the intellectual assets underlying our technologies will be vital to our eventual marketing success."

About Provectus

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies that are safer, more effective, and less invasive than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs PV-10 as a therapy for melanoma and breast cancer, and PH-10 as a topical treatment for moderate to severe psoriasis. The Company has received orphan drug designation from the FDA for metastatic melanoma. For additional information about Provectus please visit the Company’s website at or contact the Investor Relations Group via the information provided below.

Forward-Looking Statements

The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

Back to Archived News
Looking for...

  © Copyright 2013 Intellectual Property Today
Download Adobe Reader for free